Rymarz Zdort advised Nemera on the acquisition of Copernicus sp. z o.o. The final transaction documentation was executed on 27 October 2020.
Nemera is a world leader in the design, development and manufacturing of drug delivery devices, offering a comprehensive portfolio of products and services across ophthalmology, nasal, inhalation, dermal, transdermal and parenteral delivery. The acquisition of Copernicus, a Szczecin-based company that specialises in the design, development and manufacture of injection devices, and that also provides a comprehensive range of services related to the introduction of modern, intuitive drug delivery devices, not only strengthens the existing product offer of Nemera, but will also strengthen the company’s coverage in the Eastern European markets.
“Copernicus is recognised as one of the most innovative companies operating in the Polish healthcare industry; therefore, from the very beginning, our team was well aware of the crucial importance of this investment to our client. We are proud that we had an opportunity to support Nemera in such a significant transaction and we would like to thank the company for placing its trust and confidence in us”, said Dr Jakub Zagrajek, a partner in the corporate department of Rymarz Zdort.
The firm’s transaction team was led by Dr Jakub Zagrajek, assisted by attorneys from the corporate department: Dr Barbara Skardzinska, a senior associate, and Krystian Kowalski, an associate.
The team included Monika Kierepa, a partner in the corporate department who coordinated the work of the team that conducted the due diligence works.
The tax aspects of the transaction were handled by Robert Krasnodebski, a partner in the tax department, and Marek Kanczew, counsel in the same department, who also advised on employment-related issues connected with the transaction.